Angiotensin-converting enzyme 2 as a potential therapeutic target for COVID-19:A review

作     者：Bhagat Singh Dheer Singh Vinod Verma Ramakant Yadav Raj Kumar Bhagat Singh;Dheer Singh;Vinod Verma;Ramakant Yadav;Raj Kumar

作者机构：Department of Medical Laboratory TechnologyFaculty of Paramedical SciencesUttar Pradesh University of Medical SciencesEtawah206130India Department of Anaesthesiology and Critical CareUttar Pradesh University of Medical SciencesEtawah206130India Stem Cell Research CentreDepartment of HematologySanjay Gandhi Post Graduate Institute of Medical SciencesLucknow226014India Department of NeurologyUttar Pradesh University of Medical SciencesEtawah206130India Department of NeurosurgeryUttar Pradesh University of Medical SciencesEtawah206130India 

出 版 物：《Journal of Pharmaceutical Analysis》 (药物分析学报（英文版）)

年 卷 期：2022年第12卷第2期

页      面：215-220页

核心收录：

学科分类：1007[医学-药学(可授医学、理学学位)] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：COVID-19 ACE2 receptors hrsACE2 ACE inhibitors RAS AT1R blocker 

摘      要：As of August 16,2021,there have been 207,173,086 confirmed cases and 4,361,996 deaths due to the coronavirus disease(COVID-19),and the pandemic remains a global *** date,no effective and approved drugs are available for the treatment of ***-converting enzyme 2(ACE2)plays a crucial role in the invasion into host cells by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the etiological agent of ***,ACE2 density is influenced by medical conditions,such as hypertension,or by drugs,including angiotensin-converting enzyme inhibitors(ACEIs)and angiotensin receptor blockers(ARBs),which can change the fate of SARS-CoV-2 ***2 is a target for these drugs and can be manipulated to limit the viral entry and replication within the *** strategies aimed at blocking ACE2 with small molecules,peptides,and antibodies,or by neutralizing the virus through its competitive binding with human recombinant soluble ACE2(hrsACE2)are currently under *** this article,we review the current state of knowledge that emphasizes the need to find effective therapeutic agents against COVID-19 by exploiting ACE2 as a potential *** increased soluble ACE2 levels and the application of hrsACE2 in patients with COVID-19 can be implemented to control the *** has not yet been established whether hypertension and other comorbidities,independent of age,have a direct role in ***,the use of renin-angiotensin system inhibitors,ACEIs and ARBs,should not be discontinued during COVID-19 treatment.